TAK-280 is among the group's discarded projects, although it’s a T-cell engager, not an ADC.

New clinical trial entrants include the group’s attempt at targeting Sting, a field that has seen many setbacks.

CuraDev and OncoNano move into phase 1, trying to avoid the negative precedent of other Sting agonist projects.